Creelan, Ben C.
Gray, Jhanelle E.
Tanvetyanon, Tawee
Chiappori, Alberto A.
Yoshida, Takeshi
Schell, Michael J.
Antonia, Scott J.
Haura, Eric B.
Funding for this research was provided by:
Bristol-Myers Squibb
Boehringer Ingelheim
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA076292)
Article History
Received: 6 November 2018
Revised: 19 February 2019
Accepted: 27 February 2019
First Online: 18 March 2019
Competing interests
: B.C.C. discloses the following: Speaker’s Bureau: Hoffman-LaRoche AG, E.R. Squibb & Sons LLC, AstraZeneca LLC, Takeda Pharmaceutical Company Ltd, Foundation Medicine Inc. Advisory Board: E.R. Squibb & Sons LLC, AbbVie Inc., GlaxoSmithKline plc, Celgene. Contracted/Support Research Grant: Prometheus Inc., Iovance Biotherapeutics Inc., Boehringer Ingelheim GmbH. J.E.G. discloses research support from Boehringer Ingelheim GmbH and Bristol-Myers Squibb. S.J.A. has research funding from Boehringer Ingelheim. E.B.H. serves on the advisory board of Janssen Pharmaceuticals and receives research support from Forma Therapeutics and Incyte Pharmaceuticals. The other authors declare no competing interests.
: The study was institutional review board approved, Federal wide assurance number IRB00003411, Liberty Institutional Review Board, Inc. All patients provided written informed consent. The study was performed in accordance with the Declaration of Helsinki.
: Raw data and materials generated during the study are available upon request to the author study team, thoraciccro@moffitt.org.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).